Summit Therapeutics (SMMT) said Friday its partner Akeso has received approval from China's National Medical Products Administration for a second use of ivonescimab.
The approval was based on results from a phase 3 clinical trial, called HARMONi-2, which tested ivonescimab alone against pembrolizumab alone in patients with advanced non-small cell lung cancer that shows PD-L1 protein, the company said.
Following NMPA's instructions, Akeso conducted an interim analysis of overall survival and reported a hazard ratio of 0.777, based on 39% of the total data collected so far, it added.
Summit is also running the HARMONi-7 trial, a global phase 3 study evaluating ivonescimab against pembrolizumab in a similar group of NSCLC patients for regulatory approval in the United States and other licensed regions, according to the company.
Shares of the company were down nearly 32% in recent trading.
Price: 23.42, Change: -13.29, Percent Change: -36.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.